These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11816847)

  • 1. OSI-774 OSI Pharmaceuticals.
    Norman P
    Curr Opin Investig Drugs; 2001 Feb; 2(2):298-304. PubMed ID: 11816847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib OSI/Roche/Genentech.
    Kim TE; Murren JR
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1385-95. PubMed ID: 12498017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lasofoxifene: CP 336156, CP-336156.
    Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZD-1839 (AstraZeneca).
    Norman P
    Curr Opin Investig Drugs; 2001 Mar; 2(3):428-34. PubMed ID: 11575718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZD-9331 AstraZeneca.
    Niculescu-Duvaz I
    Curr Opin Investig Drugs; 2000 Sep; 1(1):141-9. PubMed ID: 11249590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
    Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept Immunex.
    Yung RL
    Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ximelagatran (AstraZeneca).
    Hopfner R
    Curr Opin Investig Drugs; 2002 Feb; 3(2):246-51. PubMed ID: 12020054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ISIS-3521. Isis Pharmaceuticals.
    Li K; Zhang J
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavopiridol. National Cancer Institute.
    Wang HK
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1149-55. PubMed ID: 11892928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology evaluation: Abarelix, Praecis pharmaceuticals.
    Doehn C; Jocham D
    Curr Opin Mol Ther; 2000 Oct; 2(5):579-85. PubMed ID: 11249760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valdecoxib (Pharmacia).
    Gotta AW
    Curr Opin Investig Drugs; 2002 Feb; 3(2):240-5. PubMed ID: 12020053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
    Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
    Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymitaq (Zarix).
    Niculescu-Duvaz I
    Curr Opin Investig Drugs; 2001 May; 2(5):693-705. PubMed ID: 11569949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BMS-275291. Bristol-Myers Squibb.
    Poulaki V
    Curr Opin Investig Drugs; 2002 Mar; 3(3):500-4. PubMed ID: 12054103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
    Wolf M; Swaisland H; Averbuch S
    Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OSI-461 (OSI).
    Galmarini CM
    Curr Opin Investig Drugs; 2004 Jun; 5(6):648-56. PubMed ID: 15242254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Iyer R; Bharthuar A
    Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.